Datapoint: Opdivo Becomes First Immunotherapy Approved to Treat Gastric Cancer
April
26
The FDA on April 16 approved Bristol Myers Squibb’s blockbuster cancer drug Opdivo as a first-line treatment for gastric cancer, gastroesophageal junction cancer and advanced or spreading esophageal adenocarcinoma. The PD-1 inhibitor is the first immunotherapy approved to treat gastric cancer. Opdivo was first approved to treat advanced melanoma in December 2014. In that indication, the drug holds covered or better status for 52% of all insured lives.
SOURCE: MMIT Analytics, as of 4/21/21
© 2025 MMIT
